Physician profile
Richard Rethorst
NPI 1770530024
$10,034.76
in general payments reported to CMS, 2019-2025
34 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $824 · 2021: $1,275 · 2022: $1,438 · 2023: $1,913 · 2024: $1,624 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,011 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,010.79 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,101.93 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,971.56 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Ucb, INC. | $662.47 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Pharmaceuticals, INC | $611.99 | 2019-2025 | Spravato, Invega Sustenna |
| Lilly USA, LLC | $535.65 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Novo Nordisk INC | $526.44 | 2019-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $481.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $444.66 | 2022-2025 | |
| Axsome Therapeutics, INC. | $418.07 | 2024-2025 | Auvelity |
| Mylan Specialty L.P. | $393.32 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $229.90 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $179.78 | 2021-2025 | Acthar |
| Viatris Specialty LLC | $163.56 | 2025 | Yupelri |
| Abbvie INC. | $142.51 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $114.21 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $113.67 | 2024-2025 | |
| Exact Sciences Corporation | $113.14 | 2023-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $94.99 | 2019 | |
| Pfizer INC. | $87.13 | 2019-2025 | |
| Genzyme Corporation | $75.09 | 2019-2020 | |
| Grifols USA, LLC | $69.55 | 2019-2024 | Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $68.73 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $67.37 | 2022-2023 | Eliquis |
| Dexcom, INC. | $61.40 | 2021-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.52 | 2019-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.64 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $46.68 | 2022-2023 | Nuzyra |
| Organon LLC | $37.07 | 2024 | |
| Abbott Laboratories | $29.97 | 2025 | Freestyle Insulinx |
| Ani Pharmaceuticals, INC. | $21.00 | 2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $19.89 | 2025 | Strensiq |
| Celgene Corporation | $18.96 | 2019 | |
| Sumitomo Pharma America, INC. | $14.59 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rethorst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.